Engineered oncolytic adenovirus (still image) (IMAGE) Emory Health Sciences Caption Engineered adenovirus Ad5-3M with highlighted in red mutations that were introduced to target virus to tumor cells, reduce inflammation, and avoid interactions with blood factors and immune cells after systemic administration. Credit Dmitry Shayakhmetov Usage Restrictions In connection with Science Translational Medicine paper License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.